Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review-Reference-Cited by-同舟云学术

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review

Published:2016-08-30 Issue:3 Volume:159 Page:425-432
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Younis T.,Rayson D.,Jovanovic S.,Skedgel C.

Funder

Atlantic Clinical Cancer Research Unit

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3954-1.pdf

Reference30 articles.

1. Lyman GH, Rolston KVI (2010) How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 6(3):149–152

2. De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM et al (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v252–v256

3. Lyman GH, Kuderer N, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857–1864

4. Lathia N, Mittmann N, DeAngelis C, Knowles S et al (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116(3):742–748

5. Crawford J, Caserta C, Roila F, ESMO Guidelines Working Group (2010) Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 21(Suppl 5):v248–v251

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP;Annals of Hematology;2023-08-21

2. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review;BMC Health Services Research;2022-12-30

3. Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada;Cancers;2022-12-15

4. Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients;Supportive Care in Cancer;2022-08-31

5. Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature;JNCI Monographs;2022-07-01